

# **Second Primary Cancer after Prostate Brachytherapy**

**Dr Darren Mitchell**  
**Consultant Clinical Oncologist**  
**Northern Ireland Cancer Centre**



Belfast Health and  
Social Care Trust



# Why?

- Atomic Bomb survivors
- Radiation workers
- Ankylosing spondylitis
- Children irradiated with benign conditions



# Why?

## CANCER RESEARCH

VOLUME 21

JULY 1961

NUMBER 6

### Second Malignancies in Prostate Carcinoma Patients after Radiotherapy Compared with Surgery

David J. Brenner, D.Sc.<sup>1</sup>  
Rochelle E. Curtis, M.A.<sup>2</sup>  
Eric J. Hall, D.Sc.<sup>1</sup>  
Elaine Ron, Ph.D.<sup>2</sup>

<sup>1</sup> Center for Radiological Research, Columbia University, New York, New York.

<sup>2</sup> Radiation Epidemiology Branch, National Cancer Institute, Bethesda, Maryland.

**BACKGROUND.** In the treatment of prostate carcinoma, radiotherapy and surgery are common choices of comparable efficacy; thus a realistic comparison of the potential long term sequelae, such as the risk of second malignancy, may be of relevance to treatment choice.

**METHODS.** Data regarding the rate of incidence from the Surveillance, Epidemiology, and End Results Program cancer registry (1973-1993) were used to compare directly second malignancy risks in 51,584 men with prostate carcinoma who received radiotherapy (3549 of whom developed second malignancies) with 70,539 men who underwent surgery without radiotherapy (5055 of whom developed

### tion in Radiation-induced Cancer\*

C. UPTON

National Laboratory,† Oak Ridge, Tennessee)

#### SUMMARY

...rently induce neoplasms of virtually all types, and dose varies, depending on the type of neo-

## Survivors

## Radiation workers

- Ankylosing spondylitis
- Children irradiated with

### Radiation Dose and Second Cancer Risk in Patients Treated for Cancer of the Cervix

JOHN D. BOICE, JR.,<sup>1,2</sup>

GÖRAN ENGHOLM,<sup>3</sup> RUTH A.

## The New England Journal of Medicine

©Copyright, 1996, by the Massachusetts Medical Society

MARCH 21, 1996

Number 12

Volume 334

### BREAST CANCER AND OTHER SECOND NEOPLASMS AFTER CHILDHOOD HODGKIN'S DISEASE

SMITA BHATIA, M.D., M.P.H., LESLIE L. ROBISON, Ph.D., ODILE OBERLIN, M.D., MARK GREENBERG, M.B., Ch.B., GRETA BUNIN, Ph.D., FRANCA FOSSATI-BELLANI, M.D., AND ANNA T. MEADOWS, M.D.



Belfast Health and Social Care Trust


# Criteria

1. Tumours should have a different histological diagnosis from the primary.
2. Appropriate latent period should be observed between the treatment of the primary tumour and the secondary cancer (>5yrs).
3. Secondary cancers should be within the radiation treatment field.

# Increased Cancer Incidence

- Radiation carcinogenesis
- Sporadic
- Genetic susceptibility
- Exogenous (Environmental factors)
- Greater follow-up





- Localised prostate cancer

Active surveillance

Radical Prostatectomy

Radical Radiotherapy

Prostate Brachytherapy

- HIFU




- Cryotherapy

- Survivorship



Belfast Health and  
Social Care Trust





# Second Malignancies in Prostate Carcinoma Patients after Radiotherapy Compared with Surgery

David J. Brenner, D.Sc.<sup>1</sup>

Rochelle E. Curtis, M.A.<sup>2</sup>

Eric J. Hall, D.Sc.<sup>1</sup>

Elaine Ron, Ph.D.<sup>2</sup>

**BACKGROUND.** In the treatment of prostate carcinoma, radiotherapy and surgery are common choices of comparable efficacy; thus a realistic comparison of the potential long term sequelae, such as the risk of second malignancy, may be of relevance to treatment choice.

- SEER database
- 3549 / 51,584 (6.8%) treated with radiotherapy.
- 5055 / 70,539 (7.1%) treated with surgery.
- Increased risk of Bladder, Colorectal and Lung  
Estimated Radiation associated solid tumours  
All years 1/290, >5years 1/125, >10years 1/70

# Evidence of Second Primary cancers in Prostate Brachytherapy

- Single institution
  - Limited statistical power.
  - Better information (dose, co-morbidities).  
H/o IBD, smoking, APC, FHx.
- Large population based studies
  - Statistical power.
  - Limitations.



# SECOND MALIGNANCIES AFTER PROSTATE BRACHYTHERAPY: INCIDENCE OF BLADDER AND COLORECTAL CANCERS IN PATIENTS WITH 15 YEARS OF POTENTIAL FOLLOW-UP

STANLEY L. LIAUW, M.D.,\* JOHN E. SYLVESTER, M.D.,<sup>†‡</sup> CHRISTOPHER G. MORRIS, M.S.,<sup>§</sup>  
JOHN C. BLASKO, M.D.,<sup>†</sup> AND PETER D. GRIMM, D.O.<sup>†</sup>

---

348 Men

Median FU 10.5years

I<sup>125</sup> Monotherapy <sup>†</sup>  
– 2 / 125 (1.6%)

I<sup>125</sup> /EBRT combined therapy  
– 13 / 213 (5.8%)


(p=0.0623)



Belfast Health and  
Social Care Trust

# SECOND MALIGNANCIES AFTER PROSTATE BRACHYTHERAPY: INCIDENCE OF BLADDER AND COLORECTAL CANCERS IN PATIENTS WITH 15 YEARS OF POTENTIAL FOLLOW-UP

STANLEY L. LIAUW, M.D.,\* JOHN E. SYLVESTER, M.D.,<sup>†‡</sup> CHRISTOPHER G. MORRIS, M.S.,<sup>§</sup>  
JOHN C. BLASKO, M.D.,<sup>†</sup> AND PETER D. GRIMM, D.O.<sup>†</sup>



# SECOND MALIGNANCIES AFTER PROSTATE BRACHYTHERAPY: INCIDENCE OF BLADDER AND COLORECTAL CANCERS IN PATIENTS WITH 15 YEARS OF POTENTIAL FOLLOW-UP

STANLEY L. LIAUW, M.D.,\* JOHN E. SYLVESTER, M.D.,<sup>†‡</sup> CHRISTOPHER G. MORRIS, M.S.,<sup>§</sup>  
JOHN C. BLASKO, M.D.,<sup>†</sup> AND PETER D. GRIMM, D.O.<sup>†</sup>



All colorectal ca pt had  
additional risk  
Factors!

# SECOND MALIGNANCIES AFTER PROSTATE BRACHYTHERAPY: INCIDENCE OF BLADDER AND COLORECTAL CANCERS IN PATIENTS WITH 15 YEARS OF POTENTIAL FOLLOW-UP

STANLEY L. LIAUW, M.D.,\* JOHN E. SYLVESTER, M.D.,<sup>†‡</sup> CHRISTOPHER G. MORRIS, M.S.,<sup>§</sup>  
JOHN C. BLASKO, M.D.,<sup>†</sup> AND PETER D. GRIMM, D.O.<sup>†</sup>

Based on SEER database information

Observed / expected

11 / 4.7 = 2.34 relative risk

Absolute risk excess of 35 per 100,000



# Cancer Incidence After Localized Therapy for Prostate Cancer

Kihyuck Moon, MD, PhD<sup>1</sup>

**BACKGROUND.** Second cancers may occur in patients who have undergone radia-

- Retrospective SEER based study
  - 297,069 men treated for prostate cancer
  - 140,767 treated >5years previously
    - Median follow-up 10.6years
    - EBRT / EBRT + Seeds / Seeds alone / No RT
    - Unlikely that 3D conformal or IMRT was used



Belfast Health and  
Social Care Trust

# Cancer Incidence After Localized Therapy for Prostate Cancer

Kihyuck Moon, MD, PhD<sup>1</sup>

BACKGROUND. Second cancers may occur in patients who have undergone radia-

	EBRT	EBRT+ seeds	Seeds	No RT
No	39,850	2219	1285	94,541
Rectum	0.44%	0.50%	0.08%	0.28%
Bladder	1.46%	1.15%	1.27%	0.89%
Lung and Bronchus	2.05%	1.68%	1.18%	1.64%



# Cancer Incidence After Localized Therapy for Prostate Cancer

Kihyuck Moon, MD, PhD<sup>1</sup>

**BACKGROUND.** Second cancers may occur in patients who have undergone radia-

	EBRT	EBRT + Seeds	Seeds
Sigmoid colon	1.26 ‡	0.93	0.25
Rectum	1.6 ‡	1.59	0.3
Bladder	1.63 ‡	1.08	1.4

# Cancer Incidence After Localized Therapy for Prostate Cancer

Kihyuck Moon, MD, PhD<sup>1</sup>

**BACKGROUND.** Second cancers may occur in patients who have undergone radia-

- Conclusion

Rates of second malignancy are low

EBRT significantly increases the risk of developing a second malignancy

BT have the lowest risk of developing a second cancer

?? Short follow-up

?? Age at treatment and other contributing factors



Belfast Health and  
Social Care Trust

# SECOND PRIMARY CANCER AFTER RADIOTHERAPY FOR PROSTATE CANCER—A SEER ANALYSIS OF BRACHYTHERAPY VERSUS EXTERNAL BEAM RADIOTHERAPY

MAY ABDEL-WAHAB, M.D.,\* ISILDINHA M. REIS, DR.P.H.,<sup>†‡</sup> AND KARA HAMILTON, M.P.H.<sup>†</sup>

- Retrospective SEER based study

228,235 men treated for prostate cancer 1988 - 2002

	No RT No Sx	EBRT	BT	EBRT+ BT
	40,433	48,400	10,223	9,096

# SECOND PRIMARY CANCER AFTER RADIOTHERAPY FOR PROSTATE CANCER—A SEER ANALYSIS OF BRACHYTHERAPY VERSUS EXTERNAL BEAM RADIOTHERAPY

MAY ABDEL-WAHAB, M.D.,\* ISILDINHA M. REIS, DR.P.H.,<sup>†‡</sup> AND KARA HAMILTON, M.P.H.<sup>†</sup>

- Retrospective SEER based study

228,235 men treated for prostate cancer 1988 - 2002

	No RT No Sx	EBRT	BT	EBRT+ BT
	40,433	48,400	10,223	9,096
Age >65	82.7%	82.1%	63.1%	64.3%
Age >75	48.7%	30%	15%	16%
Mean	73	70.5	66.7	66.7

# SECOND PRIMARY CANCER AFTER RADIOTHERAPY FOR PROSTATE CANCER—A SEER ANALYSIS OF BRACHYTHERAPY VERSUS EXTERNAL BEAM RADIOTHERAPY

MAY ABDEL-WAHAB, M.D.,\* ISILDINHA M. REIS, DR.P.H.,<sup>†‡</sup> AND KARA HAMILTON, M.P.H.<sup>†</sup>

- >1yr

EBRT significantly greater SPC than BT

- 277/100,000

EBRT significantly greater SPC than No RT/No Sx


- 207/100,000


- >5yr


EBRT significantly greater SPC than No RT/No Sx


- 475/100,000











# Conclusion

- Limited evidence currently
- Informed consent for procedure
- Ongoing prevention
  - Surveillance sigmoidoscopy 5, 10, 15yrs
    - 'RUF!'
  - Cystoscopy

